Edits/comments to therapeutics manuscript #863
Merged
Conversation
This file contains bidirectional Unicode text that may be interpreted or compiled differently than what appears below. To review, open the file in an editor that reveals hidden Unicode characters.
Learn more about bidirectional Unicode characters
|
AppVeyor build 1.0.3253 for commit 19da643 is now complete. Found 0 potential spelling error(s). Preview:... |
agitter
reviewed
Feb 15, 2021
rando2
approved these changes
Feb 15, 2021
There was a problem hiding this comment.
@SiminaB there's a lot here -- would you be able to look through these responses? I need to reach out to some of the original authors to get their input so there are several To Dos for me (and @nilswellhausen) in here as well.
| @@ -685,7 +688,7 @@ Clinical trials that are in progress are likely to provide additional insight in | |||
| Monoclonal antibodies have revolutionized the way we treat human diseases. | |||
| They have become some of the best-selling drugs in the pharmaceutical market in recent years [@doi:10.1186/s12929-019-0592-z]. | |||
| There are currently 79 FDA approved mAbs on the market, including antibodies for viral infections (e.g. Ibalizumab for HIV and Palivizumab for RSV) [@doi:10.1186/s12929-019-0592-z; @doi:10.1146/annurev-immunol-032712-095916]. | |||
| Virus-specific nAbs commonly target viral surface glycoproteins or host structures, thereby inhibiting viral entry through receptor binding interference [@doi:10.3389/fmicb.2017.02323; @doi:10.1080/21645515.2017.1337614]. | |||
| Virus-specific nAbs commonly target viral surface glycoproteins or host structures, thereby inhibiting viral entry through receptor binding interference [@doi:10.3389/fmicb.2017.02323; @doi:10.1080/21645515.2017.1337614]. <!--Are these all monoclonal? If not, the flow is a bit off--> | |||
There was a problem hiding this comment.
@nilswellhausen do you know the answer to this?
There was a problem hiding this comment.
As I said this section is outdated by now. I will try to get to this ASAP. Recombinantly expressed neutralizing antibodies such as REGN-COV2 (what former Pres. Trump got) are monoclonal. I think I need to do a better job saying that I focus on therapeutic antibodies and not the neutralizing antibodies that a person developes during an ongoing infection
There was a problem hiding this comment.
Thanks @nilswellhausen! I truly know nothing about this topic, I think I learned a little background for when I was reading through your text last year, but that's it!
rando2
reviewed
Feb 15, 2021
rando2
reviewed
Feb 15, 2021
RLordan
approved these changes
Feb 16, 2021
content/20.pharmaceuticals.md
Outdated
| Small molecule drugs include drugs targeted at viral particles, drugs targeted at host proteins, and broad spectrum pharmaceuticals, while biologics include antibodies and interferons. | ||
| As results become available from additional clinical trials, we will continue to update this manuscript to keep pace with the current understanding of which therapeutics may be effective against SARS-CoV-2 or for COVID-19. | ||
| As we cover vaccines in a separate manuscript <!--cite it when available-->, we only consider therapies for the prevention of SARS-CoV-2 infection or COVID-19 in a very limited context here, for example when a drug is studied to see whether it can prevent infection or disease in recently-exposed individuals. |
There was a problem hiding this comment.
There is a mention of this citation towards the start too if you want to change it to a url
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
|
AppVeyor build 1.0.3256 for commit 1ca0c7a is now complete. Found 0 potential spelling error(s). Preview:... |
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: Ronan Lordan <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
|
AppVeyor build 1.0.3292 for commit 93ef6cf is now complete. Found 1 potential spelling error(s). Preview:content/20.pharmaceuticals.md:561:hyperactivation... |
rando2
reviewed
Feb 16, 2021
rando2
reviewed
Feb 16, 2021
Co-authored-by: HM Rando <[email protected]>
|
AppVeyor build 1.0.3294 for commit 0788a0f is now complete. Found 1 potential spelling error(s). Preview:content/20.pharmaceuticals.md:561:overactivation... |
Added the link to the vaccine manuscript
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
|
AppVeyor build 1.0.3307 for commit 0f12c4d is now complete. Found 1 potential spelling error(s). Preview:content/20.pharmaceuticals.md:560:overactivation... |
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
Co-authored-by: HM Rando <[email protected]>
|
AppVeyor build 1.0.3314 for commit f8c6011 is now complete. Found 1 potential spelling error(s). Preview:content/20.pharmaceuticals.md:566:overactivation... |
|
AppVeyor build 1.0.3316 for commit b5fb56c is now complete. Found 1 potential spelling error(s). Preview:content/20.pharmaceuticals.md:566:overactivation... |
github-actions bot
pushed a commit
that referenced
this pull request
Feb 16, 2021
[ci skip] This build is based on a46073a. This commit was created by the following CI build and job: https://github.com/greenelab/covid19-review/commit/a46073a1342007f77fbba446872e31c505992bc3/checks https://github.com/greenelab/covid19-review/runs/572978374
github-actions bot
pushed a commit
that referenced
this pull request
Feb 16, 2021
[ci skip] This build is based on a46073a. This commit was created by the following CI build and job: https://github.com/greenelab/covid19-review/commit/a46073a1342007f77fbba446872e31c505992bc3/checks https://github.com/greenelab/covid19-review/runs/572978374
Sign up for free
to join this conversation on GitHub.
Already have an account?
Sign in to comment
Add this suggestion to a batch that can be applied as a single commit.
This suggestion is invalid because no changes were made to the code.
Suggestions cannot be applied while the pull request is closed.
Suggestions cannot be applied while viewing a subset of changes.
Only one suggestion per line can be applied in a batch.
Add this suggestion to a batch that can be applied as a single commit.
Applying suggestions on deleted lines is not supported.
You must change the existing code in this line in order to create a valid suggestion.
Outdated suggestions cannot be applied.
This suggestion has been applied or marked resolved.
Suggestions cannot be applied from pending reviews.
Suggestions cannot be applied on multi-line comments.
Suggestions cannot be applied while the pull request is queued to merge.
Suggestion cannot be applied right now. Please check back later.
Description of the proposed additions or changes
Look over the entire manuscript. I suggested changing the title to take out "prophylactics," made some changes throughout the manuscript related to this, and added more effect sizes/p-values/confidence intervals from the cited papers to make it a bit quantitative.
Related issues
Suggested reviewers (optional)
@rando2 @agitter @cgreene
Checklist